glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results FLOW: outcome for GLP-1RA Get With the FLOW! in:
Description
The studys researchers acknowledged some limitations of their study
Thanks to news reports and social media, it seems we all know someone, or know of someone, whos losing weight rapidly and effectively thanks to the GLP-1 weight loss phenomenon
one included an additional 1 mg arm [25], two had two arms of 10 and 15 mg [27,29], and one trial administered a single tirzepatide arm at the maximum tolerated dose (either 10 or 15 mg) [28]
What are common side effects reported in studies
Some medical experts are concerned that virtual care may be insufficient for prescribing weight loss drugs
